Structure Therapeutics Inc. (GPCR): auditor change — Structure Therapeutics dismisses PwC, engages EY as new auditor effective for FY2023

Structure Therapeutics Inc.

Dismissed PwC as independent auditor on May 30, 2023; PwC's reports for 2021 and 2022 were unqualified.
Engaged EY as new independent auditor for fiscal year ending December 31, 2023, effective May 31, 2023.
No disagreements between Company and PwC on accounting principles, audit scope, or procedures.
Company disclosed prior material weaknesses in internal control over financial reporting (control environment, segregation of duties, ITGC).
PwC provided letter to SEC dated June 5, 2023, agreeing with Company's statements (filed as Exhibit 16.1).

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Structure Therapeutics Inc. dismissed PricewaterhouseCoopers LLP as its auditor.

Action: dismissal
Auditor: PricewaterhouseCoopers LLP

Exact text from the filing

On May 30, 2023, the Audit Committee (the “Audit Committee”) of the Board of Directors of Structure Therapeutics Inc. (the “Company”) approved the dismissal of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Structure Therapeutics Inc. engaged Ernst & Young LLP as its auditor.

Action: engagement
Auditor: Ernst & Young LLP

Exact text from the filing

On May 30, 2023, the Audit Committee approved the engagement of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Browse all auditor changes →

Structure Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-068028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.